KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pacific Biosciences Of California (PACB) Total Liabilities (2016 - 2026)

Pacific Biosciences Of California has reported Total Liabilities over the past 16 years, most recently at $778.7 million for Q4 2025.

  • For Q4 2025, Total Liabilities rose 3.3% year-over-year to $778.7 million; the TTM value through Dec 2025 reached $778.7 million, up 3.3%, while the annual FY2025 figure was $778.7 million, 3.3% up from the prior year.
  • Total Liabilities for Q4 2025 was $778.7 million at Pacific Biosciences Of California, up from $767.1 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $1.2 billion in Q4 2021 and troughed at $753.9 million in Q4 2024.
  • A 5-year average of $1.0 billion and a median of $1.0 billion in 2024 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: surged 1449.24% in 2021 and later decreased 27.84% in 2024.
  • Year by year, Total Liabilities stood at $1.2 billion in 2021, then dropped by 0.97% to $1.2 billion in 2022, then dropped by 13.24% to $1.0 billion in 2023, then decreased by 27.84% to $753.9 million in 2024, then grew by 3.3% to $778.7 million in 2025.
  • Business Quant data shows Total Liabilities for PACB at $778.7 million in Q4 2025, $767.1 million in Q3 2025, and $764.0 million in Q2 2025.